Trial Profile
A Randomized Placebo-Controlled Phase II Trial Evaluating the Effect of Hedgehog Inhibitor LDE225 on Bone Marrow Disseminated Tumor Cells in Women With Early Stage Estrogen Receptor Negative and HER2 Negative Breast Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sonidegib (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
- Focus Pharmacogenomic; Therapeutic Use
- 31 Mar 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 06 May 2014 According to ClinicalTrials,gov record, status changed from not yet recruiting to recruiting.
- 22 Jul 2013 Planned initiation date changed from 1 Mar 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov record.